The portfolio maintains a cost advantage over competitors, priced within the least expensive fee quintile among peers.
Invesco Biotechnology & Genome ETF PBE
Morningstar’s Analysis PBE
Will PBE outperform in future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 46.8
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
---|---|---|---|
Neurocrine Biosciences Inc | 5.53 | 12.8 Mil | Healthcare |
Biomarin Pharmaceutical Inc | 5.43 | 12.6 Mil | Healthcare |
Amgen Inc | 5.05 | 11.7 Mil | Healthcare |
Vertex Pharmaceuticals Inc | 5.04 | 11.7 Mil | Healthcare |
Regeneron Pharmaceuticals Inc | 5.01 | 11.6 Mil | Healthcare |
Gilead Sciences Inc | 4.87 | 11.3 Mil | Healthcare |
Bio-Techne Corp | 4.74 | 11.0 Mil | Healthcare |
Biogen Inc | 4.61 | 10.7 Mil | Healthcare |
MannKind Corp | 3.30 | 7.7 Mil | Healthcare |
Exelixis Inc | 3.22 | 7.5 Mil | Healthcare |